Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Bacteriophage Protein Shows Antibiotic Potential

By BiotechDaily International staff writers
Posted on 27 Nov 2013
Image: Electron micrograph of bacteriophages attached to a bacterial cell (Photo courtesy of Wikimedia Commons).
Image: Electron micrograph of bacteriophages attached to a bacterial cell (Photo courtesy of Wikimedia Commons).
The T7 bacteriophage produces a protein that blocks Escherichia coli cell division and has the potential of being developed into an antibiotic-replacing drug.

T7 produces over 100 progeny per host cell in less than 25 minutes. If the T7 phage infection completes a successful growth cycle, it invariably culminates in disintegration of the host cell. Bacteriophages take over host cell resources primarily via the activity of proteins expressed early in infection. One such protein produced by the T7 phage is called Gp0.4 (gene product 0.4).

Investigators at Tel Aviv University (Israel) and their colleagues at Duke University (Durham, NC, USA) reported in the November 11, 2013, online edition of the journal, Proceedings of the National Academy of Sciences of the United States of America (PNAS) that Gp0.4 was a direct inhibitor of the E. coli filamenting temperature-sensitive mutant Z division protein.

They showed that a chemically synthesized Gp0.4 bound to purified filamenting temperature-sensitive mutant Z protein and directly inhibited its assembly in vitro. Consequently, expression of Gp0.4 in vivo was lethal to E. coli cultures and resulted in bacteria that were morphologically elongated. Furthermore, the inhibition of cell division by Gp0.4 enhanced the bacteriophage’s competitive ability by enabling them to maximize their progeny number by inhibiting escape of the daughter cells of the infected bacteria.

“Bacteria are infested with bacteriophages, which are their natural enemies and which in most cases destroy them,” said senior author Dr. Udi Qimron, professor of clinical microbiology and immunology at Tel Aviv University. “Ever since the discovery of bacteriophages in the early 20th century, scientists have understood that, on the principle of the "enemy of your enemy is your friend"; medical use could be made of phages to fight bacteria.”

“GP0.4 impedes cell division in the E. coli cell. With its capacity for cell division blocked, the bacterium continues to elongate until it dies,” said Dr. Qimron. “Potentially, this protein could be the ideal antibiotic.”

Related Links:

Tel Aviv University
Duke University



Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.